trans-1-Methoxy-2-methylcyclopentane

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: trans-1-Methoxy-2-methylcyclopentane
• 英文别名: (1R,2R)-1-methoxy-2-methylcyclopentane
• 化学式: C₇H₁₄O
• 分子量: 114.188
• InChiKey: HMMJMDWGCVGCCK-RNFRBKRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  trans-2-methylcyclopentanol 生成 trans-1-Methoxy-2-methylcyclopentane
  参考文献：
  名称：

  有机金属化合物的分子内环化IV。杂原子对有机锂化合物环化的影响

  摘要：

  烯基锂中的烷氧基可影响环化的立体化学。正丁基锂的存在增加了立体选择性，使得仅产生一种立体化学；反之，TMEDA的存在消除了杂原子的影响，因此仅产生其他立体化学。产率为33％至44％。

  DOI：

  10.1016/s0040-4039(01)82995-6

文献信息

• Treasures from the Free Radical Renaissance Period – Miscellaneous hexenyl radical kinetic data
  作者：Athelstan L. J. Beckwith、Carl H. Schiesser

  DOI：10.1039/c0ob00708k

  日期：——

  Rate constant data and Arrhenius parameters have been determined for a series of substituted hexenyl radicals of differing electronic and steric demand. Electron-withdrawing groups (CF3, CO2Et) directly attached to the radical centre slighly accelerate 5-exo ring-closure (kcis + ktrans ∼ 2.1 × 105 s−1 at 25°) relative to donating groups (OMe; 1.6 × 105 s−1 at 25°). Sterically demanding groups (tert-Bu)

  已针对一系列具有不同电子和空间需求的取代己烯基确定了速率常数数据和Arrhenius参数。相对于捐赠基团（OMe ），直接连接至自由基中心的吸电子基团（CF 3，CO 2 Et）缓慢促进5- exo闭环（25°时k cis + k trans〜2.1 ×10 5 s -1） ；在25°时为1.6×10 5 s -1）。如预期的那样，对空间要求较高的组（叔-Bu ）减慢环化过程（1×10 5 s -1）。这些观察结果与5 - exo闭环的活化能的细微变化是一致的。有趣的是，溶剂的性质似乎对该化学有重大影响，随着溶剂极性的增加，顺式/反式立体选择性有时会提高。除了包含CF 3（吸电子）基团的系统显示出环化/捕获速率常数（k c / k H）增加外，k c / k H普遍下降。记录随着溶剂极性增加的比率；据推测，这些变化主要是由于所用各种溶剂中k H的变化引起的。
• Stereochemistry of the cyclization of alkoxy-substituted 5-hexenyllithiums: effect of solvent and lithium iodide on diastereoselectivity
  作者：William F. Bailey、Xinglong Jiang

  DOI：10.1016/j.tet.2005.01.042

  日期：2005.3

  The stereochemistry of the cyclization of 4-methoxy-5-hexenyllithium, 4-(methoxymethoxy)-5-hexenyllithium, 4-tert-butoxy-5-hexenyllithium, and 3-methoxy-5-hexenyllithium, each of which was generated from the corresponding iodide by low-temperature lithium–iodine exchange, has been studied in a variety of solvent systems. The results of these studies demonstrate that the stereochemical outcome of the

  4-甲氧基-5-己烯基锂，4-（甲氧基甲氧基）-5-己烯基锂，4-叔丁氧基-5-己烯基锂和3-甲氧基-5-己烯基锂环化的立体化学通过低温锂-碘交换得到相应的碘化物，已在多种溶剂系统中进行了研究。这些研究的结果表明，烷氧基取代的5-己烯基锂环化的立体化学结果可能会受到进行闭环的介质的深刻影响。这些通常具有显着溶剂作用的病因归因于某些亲硫性配体竞争性络合碘化锂盐的能力，碘化锂盐是作为用于制备有机锂的交换反应的副产物而存在的。
• NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
  申请人：WILSON Kevin J.

  公开号：US20150258074A1

  公开（公告）日：2015-09-17

  Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).

  本发明揭示了具有吡唑吡啶基础结构的公式（1.0）的ERK抑制剂及其药学上可接受的盐。本发明还揭示了使用公式（1.0）的化合物治疗癌症的方法。
• COMPOUNDS
  申请人：Mciver Edward Giles

  公开号：US20100317646A1

  公开（公告）日：2010-12-16

  A compound of formula I, or a pharmaceutically acceptable salt or ester thereof, wherein R 1 is selected from: aryl; heteroaryl; —NHR 3 ; fused aryl-C 4-7 -heterocycloalkyl; —CONR 4 R 5 ; —NHCOR 6 ; —C 3-7 -cycloalkyl; —O—C 3-7 -cycloalkyl; —NR 3 R 6 ; and optionally substituted —C 1-6 alkyl; wherein said aryl, heteroaryl, fused aryl-C 4-7 -heterocycloalkyl and C 4-7 -heterocycloalkyl are each optionally substituted; R 2 is selected from hydrogen, aryl, C 1-6 -alkyl, C 2-6 -alkenyl, C 3-7 -cycloalkyl, heteroaryl, C 4-7 heterocycloalkyl and halogen, wherein said C 1-6 -alkyl, C 2-6 -alkenyl, aryl, heteroaryl and C 4-7 -heterocycloalkyl are each optionally substituted; R 3 is selected from aryl, heteroaryl, C 4-7 -heterocycloalkyl, C 3-7 -cycloalkyl, fused aryl-C 4-7 -heterocycloalkyl and C 1-6 -alkyl, each of which is optionally substituted; R 4 and R 5 are each independently hydrogen, or optionally substituted C 3-7 -cycloalkyl, aryl, heteroaryl, C 1-6 -alkyl or C 3-6 -heterocycloalkyl; or R 4 and R 5 together with the N to which they are attached form a C 3-6 -heterocycloalkyl ring; each R 6 is independently selected from C 1-6 -alkyl, C 3-7 cycloalkyl, C 4-7 -heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted each R 7 is selected from hydrogen, optionally substituted C 1-6 -alkyl and C 3-7 -cycloalkyl; each of R 8 and R 9 is independently hydrogen or optionally substituted C 1-6 -alkyl; or R 8 and R 9 together with the N to which they are attached form a C 4-6 -heterocycloalkyl; each R 10 is selected from C 3-7 -cycloalkyl and optionally substituted C 1-6 -alkyl; each R 11 is independently selected from C 1-6 -alkyl, C 3-7 -cycloalkyl, C 1-6 alkyl-C 3-7 -cycloalkyl, C 4-7 -heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted; A is selected from halogen, —NR 4 SO 2 R 5 , —CN, —OR 6 , —NR 4 R 5 , —NR 7 R 11 , hydroxyl, —CF 3 , —CONR 4 R 5 , —NR 4 COR 5 , —NR 7 (CO)NR 4 R 5 , —NO 2 , —CO 2 H, —CO 2 R 6 , —SO 2 R 6 , —SO 2 NR 4 R 5 , —NR 4 COR 5 , —NR 4 COOR 5 , C 1-6 -alkyl and —COR 6 . Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula I.

  化合物I的公式，或其药学上可接受的盐或酯，其中R1选自：芳基；杂环芳基；—NHR3；融合的芳基-C4-7-杂环烷基；—CONR4R5；—NHCOR6；—C3-7-环烷基；—O—C3-7-环烷基；—NR3R6；和可选择取代的—C1-6烷基；其中所述的芳基，杂环芳基，融合的芳基-C4-7-杂环烷基和C4-7-杂环烷基均可选择取代；R2选自氢，芳基，C1-6-烷基，C2-6-烯基，C3-7-环烷基，杂环芳基，C4-7-杂环烷基和卤素，其中所述的C1-6-烷基，C2-6-烯基，芳基，杂环芳基和C4-7-杂环烷基均可选择取代；R3选自芳基，杂环芳基，C4-7-杂环烷基，C3-7-环烷基，融合的芳基-C4-7-杂环烷基和C1-6-烷基，每种均可选择取代；R4和R5各自独立地选自氢，或可选择取代的C3-7-环烷基，芳基，杂环芳基，C1-6-烷基或C3-6-杂环烷基；或R4和R5与它们连接的N一起形成C3-6-杂环烷基环；每个R6各自独立地选自C1-6-烷基，C3-7-环烷基，C4-7-杂环烷基，芳基和杂环芳基，每种均可选择取代；每个R7选自氢，可选择取代的C1-6-烷基和C3-7-环烷基；每个R8和R9各自独立地选自氢或可选择取代的C1-6-烷基；或R8和R9与它们连接的N一起形成C4-6-杂环烷基；每个R10选自C3-7-环烷基和可选择取代的C1-6-烷基；每个R11各自独立地选自C1-6-烷基，C3-7-环烷基，C1-6-烷基-C3-7-环烷基，C4-7-杂环烷基，芳基和杂环芳基，每种均可选择取代；A选自卤素，—NR4SO2R5，—CN，—OR6，—NR4R5，—NR7R11，羟基，—CF3，—CONR4R5，—NR4COR5，—NR7（CO）NR4R5，—NO2，—CO2H，—CO2R6，—SO2R6，—SO2NR4R5，—NR4COR5，—NR4COOR5，C1-6-烷基和—COR6。进一步方面涉及公式I化合物的制药组合物，治疗用途和制备过程。
• Cyclization of (4-Methoxy-5-hexenyl)lithium
  作者：William F. Bailey、Xing-Long Jiang

  DOI：10.1021/jo00101a010

  日期：1994.11

  The cyclization of (4-methoxy-5-hexenyl)lithium (1), which was prepared by lithium-iodine exchange between 3-methoxy-6-iodo-1-hexene (2) and 1.75 molar equiv of t-BuLi in diethyl ether-n-pentane solution at -78 degrees C, has been investigated in a variety of solvent systems. The isomeric composition of the cis- and trans-1-methoxy-2-methylcyclopentane produced upon cyclization of 1 followed by quench with MeOH has been found to be dramatically dependent on the solvent system in which the isomerization is conducted.